

SANUWAVE Health, Inc.  
Form 8-K  
April 03, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date  
of  
Report  
(Date of  
of  
earliest  
event  
reported)  
**March 31, 2014**

**SANUWAVE  
Health, Inc.**  
(Exact name  
of registrant  
as specified in  
its charter)

**Nevada**                      **000-52985 20-1176000**  
(State or other jurisdiction (Commission(IRS Employer  
File  
of incorporation)              Number)      Identification No.)

**30023  
Great  
Oaks**

**Way,  
Suite  
150,  
Alpharetta,  
Georgia**

(Address  
of  
~~(Zip Code)~~  
executive  
offices)

Registrant's  
telephone  
~~(678)~~  
**581-6843**  
area  
code

**N/A**  
(Former  
name or  
former  
address, if  
changed  
since last  
report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 2.02 Results of Operations and Financial Condition.**

On March 31, 2014, SANUWAVE Health, Inc., a Nevada Corporation (the "Company"), announced its financial results for the year ended December 31, 2013. A copy of the related press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

The information in this Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 7.01 Regulation FD Disclosure.**

The Company hosted a conference call with investors on April 1, 2014 at 10 a.m., Eastern Time, to discuss the financial results for the year ended December 31, 2013 and provide a clinical and funding update. A copy of management's prepared remarks is attached hereto as Exhibit 99.2.

The information in this Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.    Description

|      |   |
|------|---|
| 99.1 | Press release, dated March 31, 2014, issued by SANUWAVE Health, Inc.  |
| 99.2 | Management's prepared remarks for the April 1, 2014, SANUWAVE Health, Inc. conference call to discuss the year ended December 31, 2013 financial results and provide a clinical and funding update. |



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SANUWAVE HEALTH, INC.

Dated: April 3, 2014

By: */s/ Barry J. Jenkins*

Name: Barry J. Jenkins

Title: Chief Financial Officer

---

**EXHIBIT INDEX**

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1               | Press release, dated March 31, 2014, issued by SANUWAVE Health, Inc.  |
| 99.2               | Management's prepared remarks for the April 1, 2014, SANUWAVE Health, Inc. conference call to discuss the year ended December 31, 2013 financial results and provide a clinical and funding update. |